1. Home
  2. BIAF vs DRCT Comparison

BIAF vs DRCT Comparison

Compare BIAF & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIAF
  • DRCT
  • Stock Information
  • Founded
  • BIAF 2014
  • DRCT 2018
  • Country
  • BIAF United States
  • DRCT United States
  • Employees
  • BIAF N/A
  • DRCT N/A
  • Industry
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • DRCT Computer Software: Programming Data Processing
  • Sector
  • BIAF Health Care
  • DRCT Technology
  • Exchange
  • BIAF Nasdaq
  • DRCT Nasdaq
  • Market Cap
  • BIAF 7.6M
  • DRCT 8.8M
  • IPO Year
  • BIAF 2022
  • DRCT 2022
  • Fundamental
  • Price
  • BIAF $3.24
  • DRCT $0.29
  • Analyst Decision
  • BIAF Hold
  • DRCT Strong Buy
  • Analyst Count
  • BIAF 1
  • DRCT 1
  • Target Price
  • BIAF N/A
  • DRCT $6.00
  • AVG Volume (30 Days)
  • BIAF 7.6M
  • DRCT 1.8M
  • Earning Date
  • BIAF 11-13-2025
  • DRCT 11-11-2025
  • Dividend Yield
  • BIAF N/A
  • DRCT N/A
  • EPS Growth
  • BIAF N/A
  • DRCT N/A
  • EPS
  • BIAF N/A
  • DRCT N/A
  • Revenue
  • BIAF $7,681,059.00
  • DRCT $36,459,000.00
  • Revenue This Year
  • BIAF N/A
  • DRCT $16.81
  • Revenue Next Year
  • BIAF $20.04
  • DRCT $35.28
  • P/E Ratio
  • BIAF N/A
  • DRCT N/A
  • Revenue Growth
  • BIAF 4.99
  • DRCT N/A
  • 52 Week Low
  • BIAF $2.34
  • DRCT $0.28
  • 52 Week High
  • BIAF $67.12
  • DRCT $6.59
  • Technical
  • Relative Strength Index (RSI)
  • BIAF 53.34
  • DRCT 33.87
  • Support Level
  • BIAF $2.36
  • DRCT $0.29
  • Resistance Level
  • BIAF $7.29
  • DRCT $0.39
  • Average True Range (ATR)
  • BIAF 0.63
  • DRCT 0.05
  • MACD
  • BIAF -0.30
  • DRCT -0.00
  • Stochastic Oscillator
  • BIAF 23.73
  • DRCT 4.72

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

Share on Social Networks: